Hemogenyx Pharmaceuticals PLC @HemogenyxPharma Twitter profile | Pikagi

Pikagi

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2,114

Followers

200

Following

96

Media

524

Statuses

Hemogenyx Pharmaceuticals PLC. We are focused on bringing our cell therapy and immunotherapies to patients in need. (LON:HEMO)

New York, NY London, UK

https://t.co/2DqCzy6rlX

Joined January 2014

Don't wanna be here? Send us removal request.

Pinned Tweet

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

1 year

"🌟 Witness the cutting-edge innovation of @HemogenyxPharma as they revolutionize drug development!Their groundbreaking methods and technologies are saving lives by creating new and effective medicines. Join the journey of scientific discovery and hope! 🚀

Tweet card media

Hemogenyx Pharmaceuticals Overview 2023

www.youtube.com

1

9

42

Last Seen Profiles

@TheAtlasCouple

@TERR0RINCARNATE

@788Ck

@AuraHaver

@x_x2ds_

@shahidkhan_y

@AlEmbBulgaria

@G_villeBaseball

@DioBrandoLmao

@queerenbyepi

@XChecks_

@NiallKeepsMum

@Maria_Gouleva

@erll_87

@studioJAM3

@iamOmotara

@CamoKai_86

@rRvYEUXdlor9nUS

@sakimichanmale

@sibaena_games

@SaKuTaS_

@jandakembangstw

@Halpy_

@michelle_m23_

@Lyrahfans

@jandakembangstw

@iy_ehime

@knivecut

@Patrick_GOW

@jammehso20

@abefnd_rdc

@wardsrbms

@bellshoals

@Alissonbecker

@vannia_aurora

@STATIKLNK

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Our scientists are moving forward in their fight against #COVID19 We are proud to be called “A Life Saving Company”.

Tweet media one

9

34

93

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We have multiple collaboration agreements. Several of our product candidates have at least one agreement with a biopharmaceutical company... ...we have six of our product candidates in pipeline compared with two when #HEMO first listed.

Tweet media one

1

15

69

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

The team of @HemogenyxPharma is honing its manufacturing skills. All efforts are to get our first product candidate #CAR_T to the #clinic , to the #patients suffering from #AML

3

15

70

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office.

Tweet media one

1

22

71

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

We are happy to report that the 2nd process development run of HEMO-CAR-T cell manufacturing in our cGMP compliant clean rooms was successful. Our amazing team of scientists are moving toward engineering runs (PQ- process qualifications) of HEMO-CAR-T cells production.

3

4

60

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We have made further patent applications in relation both to HEMO-CAR-T and to the CDX bi-specific antibodies, the latter being a joint application with GlobalCo. Further information will be disclosed regarding these in due course. #HEMO #NewTherapies

Tweet media one

0

17

60

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement (“Agreement”) with Eli Lilly and Company (“Lilly”),

3

22

62

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

Another day for @HemogenyxPharma and another step closer towards the clinic… #HEMO #biopharmaceutical

6

13

61

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

CAR-T can give long-lasting remission from blood cancers. #HEMO is proud to work with Dr June's Center for Cellular Immunotherapies at the University of Pennsylvania to take HEMO-CAR-T to clinical trials.

Tweet card media

First patients of pioneering CAR T-cell therapy ‘cured of cancer’

Cancer-killing cells still present 10 years on, with results suggesting therapy is a cure for certain blood cancers

www.theguardian.com

2

16

61

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and issued by the United States Patent and Trademark Office.

Tweet media one

3

18

56

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce that a new corporate #HEMO presentation is now available on our website and on the link below…

Tweet media one

0

21

59

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

We have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus.

5

13

55

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

We are happy to report that the 1st process development run of HEMO-CAR-T cell manufacturing in our cGMP compliant clean rooms was successful (10days). Our amazing team of scientists are moving toward engineering runs (PQ- process qualifications) of HEMO-CAR-T cells production.

6

10

56

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

We would like to thank our scientists, directors, consultants, and support staff for their hard work and dedication in the departing 2020! We would also like to thank our followers and investors for their unwavering support of #HemogenyxPharma .

5

1

56

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce that we have signed a licence agreement with the global biopharmaceutical company @LillyPad Under this Agreement, Eli Lilly grants #HEMO an exclusive worldwide licence to certain intellectual property.

Tweet media one

2

18

52

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce a further key step in the development of our CDX programme… #HEMO and @SelexisSA have signed a service agreement to develop the cell line for our CDX bispecific antibody for the treatment of acute myeloid leukemia.

Tweet media one

0

18

53

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

9 months

Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of #Cancer

Tweet card media

Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer

Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer

stocks.apple.com

3

13

52

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce significant progress in relation to moving our lead product candidate Chimeric Antigen Receptor T-cells toward clinical trials. #HEMO has applied for a pre-Investigational New Drug application meeting with the FDA…

Tweet media one

2

13

52

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

We are a pre-clinical stage biopharmaceutical group developing new medicines and treatments for blood, autoimmune disease and bone marrow transplantation to a greater number of patients. ...Please visit our website to find out a little more :

Tweet media one

1

9

50

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

A day in @HemogenyxPharma - a step closer to the clinic… #HEMO #biopharmaceutical

6

12

50

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

The team of @HemogenyxPharma is making sure that their product candidate #CAR_T is stable, delivered to #patients suffering from #AML by a reliable partner with established logistics including real-time GPS tracking anywhere in the US. Quality System!

2

4

51

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

We announce the successful completion of our second Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice compliant clean rooms.

Tweet card media

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed

stocks.apple.com

2

6

50

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Want to understand a little more about the significance of today’s RNS and what this really means? What is #HEMO -CAR-T ? “HEMO-CAR-T is made using @HemogenyxPharma proprietary humanised monoclonal antibody against a target on the surface of AML cells”

Tweet media one

1

18

48

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to issue an update on the development of our leading product candidate Chimeric Antigen Receptor T-cells...

Tweet media one

2

15

49

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

£60 Million will allow Hemogenyx Pharmaceuticals to accelerate the development and marketability of its product candidates as follows: 1. Achieve clinical proof of concept for the Company's CDX bi-specific antibody product candidate if and when needed including:

3

8

47

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Our #HEMO scientists on a business trip to Maryland… …A short break on the way back to NY. From Left to right: Senior Scientist Dr. Ronen Ben Jehuda Director of preclinical development Dr. Elina Shrestha, Senior Scientist Dr. Raymond Liang.

Tweet media one

3

8

48

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

1 year

We are pleased to announce the successful completion of a full set of analytical tests required to verify the quality of the cells manufactured during three Process Qualification ("PQ") runs of the end-to-end process for HEMO-CAR-T production.

4

10

47

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

7 months

FDA Consents to Phase I Trials of HEMO-CAR-T

5

9

46

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“This is the next incredibly important step on a direct path to clinical proof of concept for one of our leading product candidates....we believe this will have a significant and positive impact in the treatment of acute myeloid leukemia” CEO & Co-Founder of #HEMO Dr @vmsandler

Tweet media one

0

13

44

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

In this short video listen to #HEMO CEO and Co-Founder @vmsandler comment on the development of HEMO-CAR-T which is progressing as we enter the manufacturing phase…

4

14

45

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce the commencement of a #HEMO strategic manufacturing partnership with WuXi ATU, a global contract testing development and manufacturing organisation.

Tweet media one

2

11

47

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We anticipate finalisation of the CDX antibody agreement and completion of commercial discussions with GlobalCo and for the continued development of CBR. #HEMO has now been able to make strong progress across its main projects…

Tweet media one

2

15

46

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

1 year

Hemogenyx Pharmaceuticals announces the submission of an IND application seeking authorization from the FDA to begin a Phase I clinical trial of its lead product candidate HEMO-CAR-T for treating acute myeloid leukemia.

2

15

42

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…We are delighted to partner with @SelexisSA and access its proprietary protein expression tools and technologies, IP and know-how. The partnership is key to advancing our CDX programme into clinical trials…” #HEMO CEO and co-founder @vmsandler

Tweet media one

1

14

45

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

The team of @HemogenyxPharma is engaged in aseptic simulation. All efforts are to get our first product candidate #CAR_T to the #clinic , to the #patients suffering from #AML safely!

0

6

46

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

First #Canadian #process #development #CAR_T run was a definite #success . One more run outside and we will be ready to start using our own #cleanrooms preparing for formal engineering runs of our own #CAR_T product candidate. #HEMO #team ROCKS!

7

8

44

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

For over 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases… Our #HEMO technology has the potential to enable many more patients suffering from devastating blood diseases to benefit from bone marrow transplantation.

Tweet media one

1

19

42

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased with the continued interest of GlobalCo in facilitating the advancement of the CDX antibody toward the clinic, having concluded the successful development phase of this product candidate, and excited about the progress in moving #HEMO -CAR-T toward clinical trials.

Tweet media one

3

14

45

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Based on an in-house test all US employees (as of today) are negative for the anti- #SARSCoV2 #virus #antibodies . Social distancing and diligent use of PPE work. These allowed us to never stop advancing toward our main goal - Saving Patients Lives. We are "a life saving company"

5

11

45

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Every step of the manufacturing of our #HEMO CAR-T for #AML must be made perfect. A patient to be treated will have only one chance! Our scientists and partners are determined to help the patients to survive and ultimately get cured…

2

6

44

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

“…We believe it is a ground-breaking new approach to treat emerging viral infections and to potentially become an effective new form of #cancer treatment…” @vmsandler CEO & Co-Founder of #HEMO

Tweet media one

0

16

39

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

AML, the most common type of acute leukemia in adults, has poor survival rates and is currently treated using chemotherapy rather than the potentially more benign and effective form of therapy being developed by #HEMO For more specific info click here :

Tweet media one

1

15

44

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We at #HemogenyxPharma are focused on bringing our cell therapy and immunotherapies to patients in need.

1

7

43

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

5 months

U.S. Application No. 17/133,448 Title: METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES Applicant: HEMOGENYX LLC Inventor: Vladislav Sandler Issued as U.S. Patent No. 11,945,866 on April 2, 2024.

2

12

44

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

The team of @HemogenyxPharma always remembers two numbers: 75 and 50. 75 people are diagnosed with #AML and 50 people die of AML each day in the US. We want to drastically reduce mortality caused by #AML Every day we work to save lives and improve the World.

2

3

42

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…The issue of this patent is of considerable significance for the Company because it protects the IP for both CDX and HEMO-CART-T product candidates…” #HEMO CEO & Co-Founder @vmsandler

Tweet media one

2

13

43

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…This is a vital next step on a direct path toward clinical trials for one of our leading product candidates…” @vmsandler CEO & Co-Founder of #HEMO

Tweet media one

1

13

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

We are pleased to announce that we have achieved proof of concept for our Chimeric Bait Receptor platform technology. #HEMO has filed a seminal provisional patent application protecting its rights to the intellectual property covering CBR.

Tweet media one

4

19

43

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are a pre-clinical stage biopharmaceutical group developing new medicines and treatments for blood, autoimmune disease and bone marrow transplantation to a greater number of patients. ...Please see our new presentation below for further information.

Tweet media one

0

14

41

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of New York, adjacent to Columbia University and City College.

Tweet media one

0

10

42

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

1 year

This application follows successful work on manufacturability, quality, safety and other key parts of the development of HEMO-CAR-T. Once the proposed clinical investigation plan has been cleared to proceed by the FDA, the Company plans to initiate a Phase I clinical trial.

3

4

41

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Our first small publication is out at ASH/Blood “FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal Hematopoietic Progenitors and AML in Humanized Mouse Models” Clinical proof of concept is to follow.

Tweet card media

FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal Hematopoietic Progenitors and AML in...

Acute myeloid leukemia (AML) is a blood cancer arising from clonal proliferation of myeloid progenitors harboring oncogenic mutations. AML patients have po

ashpublications.org

3

7

41

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Financing Facility of up to £60 Million

3

8

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“There’s an urgent clinical need for effective treatments for AML. WuXi ATU is proud to manufacture & test the lentiviral vectors that #HEMO requires to accelerate the beginning of its first clinical trial for this indication” WuXi ATU CEO Dr David Chang

Hemogenyx Pharmaceuticals partnership with WuXi ATU

Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies’...

0

8

42

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce our participation in the @HCWCO Bioconnect Conference, in which #HEMO will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.

Tweet media one

1

16

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly")

Tweet card media

Hemogenyx Pharmaceuticals PLC Announces Further re Development Agreement

Hemogenyx Pharmaceuticals plc (LSE:HEMO) ("Hemogenyx Pharmaceuticals" or the "Company") On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo...

www.biospace.com

1

7

41

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

CAR-T Agreement with University of Pennsylvania #Penn

0

13

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…I am very excited to be on the West Side of Manhattan in the historic Manhattanville Factory District. We will be growing our staff and operations significantly over the next three years…” Co-Founder and #HEMO CEO @vmsandler

Tweet media one

2

8

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

A very good paper that describes how #COVID19 starts and develops and what intervention methods might be feasible "most patients develop neutralizing antibodies by week 3" If discovered, made into a drug and applied early neutralizing antibodies may help!

Tweet card media

The trinity of COVID-19: immunity, inflammation and intervention

Nature Reviews Immunology - In the short time since SARS-CoV-2 infections emerged in humans, much has been learned about the immunological processes that underlie the clinical manifestation of...

2

23

38

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“While progress towards the next stage with GlobalCo on the CDX antibody is continuing, we have made significant steps in relation to HEMO-CAR-T. It’s efforts to combat viral pathogens such as COVID-19 are encouraging” Sir Marc Feldmann, #HEMO Chairman

Tweet media one

1

17

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…This agreement is key to advancing our HEMO-CAR-T programme into clinical trials and accelerating the timeline to deliver this innovative therapy to patients in need of a more benign and effective treatment for AML…” @vmsandler #HEMO CEO & co-founder

Tweet media one

2

9

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to issue an update on negotiations regarding the future development of our leading product candidate CDX bispecific antibody for the treatment of acute myeloid leukemia...

Tweet media one

0

12

39

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

HEMO-CAR-T 3rd Process Qualification Run Completed

0

6

39

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

Here, our Founder and CEO @vmsandler catches up with @TMSreach Listen to Vlad expand about the very large patent application, why every year is a company making year, and the massive cost savings the custom-built laboratory will make for #HEMO

4

14

39

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Why #HEMO chose to take space at the Manhattanville Factory District campus… "We are a small company that is growing very fast, and because we are growing fast and we're about to enter clinical trials, we need to expand” @vmsandler via @NYBizJournal

Tweet card media

Why Hemogenyx Pharmaceuticals chose to take space at the Manhattanville Factory District campus

Biopharmaceutical company Hemogenyx Pharmaceuticals LLC has signed a deal to move to the Manhattanville Factory District campus in West Harlem. Here's why.

www.bizjournals.com

1

8

40

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

7 months

Hemogenyx Pharmaceuticals has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered into the brain via programmed microglial cells for the potential treatment of brain cancers and certain neurodegenerative diseases

1

13

38

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

7 months

Chimeric Bait Receptor ("CBR") can be delivered intranasally in the form of messenger RNA ("mRNA") for the potential treatment of airborne viral infections.

0

14

38

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce the appointment of Dr Alan E. Walts, who joins the #HEMO team. The renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management.

Tweet media one

2

13

39

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Please, listen to the #HEMO podcast here:

Tweet card media

Hemogenyx Pharmaceuticals Podcast

www.youtube.com

6

7

37

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…The successful completion of the licence agreement with @LillyPad represents a real milestone in the development of #HEMO …” @vmsandler CEO & Co-Founder of Hemogenyx Pharmaceuticals

Tweet media one

2

11

37

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Here, @byFionaMacRae of the @DailyMailUK writes an interesting article “In trials, all signs of cancer disappeared in more than 80 per cent of patients with acute lymphoblastic leukaemia — the most common cancer in children — after receiving CAR T-cells”

Tweet card media

Stunning therapy lands knock-out blow to cancer

Patients who had exhausted all other options and been told they had just months to live have gone into remission. Others have even been cured by the one-off dose.

www.dailymail.co.uk

1

8

38

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

All our Friends are invited to celebrate the opening of Hemogenyx Pharmaceutical’s Manhattan R&D facility on Thursday, August 11 at 14:00 ET. Please, join us for a drink, a bite, and a good laugh! #HEMO is moving forward! 1361 Amsterdam Ave, Ste. 320 New York, NY 10027

3

9

36

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Here, our CEO @vmsandler catches up with @TMSreach once again and expands on news of the recent agreement with biopharmaceutical company @LillyPad which granted #HEMO an exclusive world-wide license to an antibody that can be used to treat blood cancers.

Hemogenyx Pharmaceuticals PLC - Total Market Solutions

Chief negotiators for Hemogenyx Pharmaceuticals make miracles as they regain control of the CDX antibody at the heart of the business

total-market-solutions.com

1

9

36

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

#HEMO will become a clinical-stage #biotechnology company with a pipeline of product candidates in clinical trials!

1

4

36

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Draw Down Under Financing Facility Agreement The use of the Financing Facility will enable #HEMO to move our life-saving technologies forward rapidly, placing the Company in a highly competitive position in the treatment of cancer and viral diseases.

1

9

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

@HemogenyxPharma is moving a step closer to its first clinical trials for HEMO-CAR-T for #AML The first trial training run of the first step of cell manufacturing - cell wash procedure in our own clean room!

3

8

35

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

#HEMO We are hiring #Manufacturing #Associate for production of our first #CART living #drug candidate for the treatment of #AML

Manufacturing Associate - Cell Therapies CAR-T - New York City, NY

About Hemogenyx Pharmaceuticals, LLC Hemogenyx Pharmaceuticals LLC is a pre-clinical stage biopharmaceutical group developing new medicines and t...

jobs.sciencecareers.org

0

8

36

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Hemogenyx Pharmaceuticals plc announces half-year report. “The Company is on track to achieve the inflection point in its development” #HEMO

3

9

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

CAR-T Master Translational Agreement with the University of Pennsylvania - a milestone in the development of our CAR-T program.

4

6

36

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

We are pleased to announce the successful completion of our first Process Qualification (“PQ”) run of the end-to-end process for the manufacture of HEMO-CAR-T cells.

3

7

35

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

A message of the CEO Vladislav Sandler on the fundraising.

Tweet card media

Fundraise Completed

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, is pleased to announce that the Company has raised £2,500,000 (before expenses) throu...

www.youtube.com

9

8

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

10 months

Lentivirus re-manufacturing completed.

Tweet card media

Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed

Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed

stocks.apple.com

3

6

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

We believe that we can transform patients’ lives by delivering breakthrough therapies... ...We also believe that good business means healthy people and a better world. Follow us on @YouTube to find out a little more about what we do

Tweet media one

2

7

35

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

Hemogenyx Pharmaceuticals opens custom R&D facility in Manhattanville

Hemogenyx Pharma opens custom R&D facility in Manhattanville

Hemogenyx Pharmaceuticals opened its new custom-engineered R&D facility at the Mink Building in West Harlem’s Manhattanville Factory District of New York City, adjacent to Columbia University and...

pharmaceuticalmanufacturer.media

0

7

35

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Our Broker, @SPAngelNews has published a research note on #HEMO Please click below to view this latest coverage :

Tweet media one

1

16

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

#HemogenyxPharma announces SAFE-HEMO-CAR-T, a new controllable CAR-T is effective against AML in vitro.

1

12

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We are pleased to announce our results for the year ended 31 December 2020...

Tweet media one

0

7

33

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

@HemogenyxPharma is moving the third step closer to its first clinical trials for HEMO-CAR-T for #AML . The first trial run for the third step of cell manufacturing- T cell transduction and expansion in our own clean room!

2

5

33

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

Update on CDX Antibody Development

1

6

33

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…Our presentation at the @HCWCO Bioconnect Investment Conference provides #HEMO with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally…” CEO & Co Founder @vmsandler

Tweet media one

0

12

33

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

“…The process toward our IND application remains on track and the change in the FDA's process is not expected to affect the outcome of the IND application or timetable for clinical trials…” Dr @vmsandler CEO & Co-Founder of #HEMO

Tweet media one

1

10

33

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

Terminal cleaning of our clean rooms is in progress. This is a pre-requisite for a GMP certification necessary to manufacture our #CART therapy. #HEMO . We are moving toward the clinic!

5

5

32

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

5 months

Hemogenyx Pharmaceuticals important raise and CAR-T potential makes it one to watch

Tweet card media

Hemogenyx Pharmaceuticals important raise and CAR-T potential makes it one to watch

In a recent article, I said at least 20 micro-cap life sciences stocks were waiting to pop once interest returned to the sector. Investors can now add...

www.proactiveinvestors.co.uk

0

11

34

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Hemogenyx Pharmaceuticals is seeking a cell therapy manufacturing associate to support its cell therapy program towards in-human clinical studies… …to join the #HEMO Team please see our website below for more details :

Tweet media one

1

8

33

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

2 years

@HemogenyxPharma is moving the second step closer to its first clinical trials for HEMO-CAR-T for #AML . The first trial run for the second step of cell manufacturing- T cell isolation in our own clean room!

1

5

32

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

We can announce that Andrew Wright, our Company's Financial Controller and Company Secretary has purchased 94,882 shares in #HEMO at an average price of 6.03p per share. Following this transaction, Mr Wright has a total interest in 1,626,991 Shares.

Tweet media one

1

5

31

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

3 years

Here, our #HEMO CEO @vmsandler catches up with @TMSreach once again… “We’re about making drugs to treat patients, save lives and everything else will follow…including the share price”

1

12

31

@HemogenyxPharma

Hemogenyx Pharmaceuticals PLC

@HemogenyxPharma

4 years

We have provided an outstanding return on investment to our shareholders increasing the value of #HEMO by more than 490% in 2020. Given numerous reported developments, we have no doubt that the next year will be transformational for our company.

2

2

29